49791-37-9

Usage

Uses

Used in Pharmaceutical Industry:
OXO-PYRROLIDIN-1-YL-ACETIC ACID is used as a cognitive enhancer for its potential to improve memory, learning, and focus. It is particularly beneficial for individuals seeking to enhance their cognitive performance.
Used in Neurological Applications:
OXO-PYRROLIDIN-1-YL-ACETIC ACID is used as a treatment for cognitive impairment and dementia, given its potential to ameliorate symptoms associated with these conditions.
Used in Neuroprotection:
OXO-PYRROLIDIN-1-YL-ACETIC ACID is used as a neuroprotective agent to help protect the brain from damage caused by various toxins and injuries, due to its ability to modulate neurotransmitter release and support brain health.
While Oxiracetam shows promise in these applications, ongoing research is necessary to fully elucidate its benefits and potential risks, ensuring its safe and effective use in various settings.

InChI:InChI=1/C6H9NO3/c8-5(6(9)10)7-3-1-2-4-7/h1-4H2,(H,9,10)

Upstream product

• 41600-21-9 methyl 2-oxo-2-(pyrrolidin-1-yl)acetate 
• 123-75-1 pyrrolidine 
• 17118-74-0 ethyl oxalylchloride 
• 41600-22-0 Ethyl-α-oxopyrrolidin-1-acetat 

Relevant academic research and scientific papers

Direct C-H Functionalization of Phenanthrolines: Metal- And Light-Free Dicarbamoylations

A direct method for C-H dicarbamoylations of phenanthrolines has been developed, which is capable of directly installing primary, secondary as well as tertiary amides. This is a significant improvement on the previous direct method, which was limited to primary amides. The metal-, light-, and catalyst-free Minisci-type reaction is cheap, operationally simple, and scalable. We demonstrate that the step efficiency toward dicarbamoylated phenanthroline targets can now be significantly improved.

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Design, synthesis, structure, and acaricidal/insecticidal activity of novel spirocyclic tetronic acid derivatives containing an oxalyl moiety

A series of novel spirocyclic tetronic acid derivatives containing an oxalyl moiety was designed and synthesized via the key intermediate 3-(2,4,6-trimethyl)-2-oxo-1-oxaspiro[4.4]-decyl-3-en-4-ol. The target compounds were identified by 1H NMR and elemental analysis or high-resolution mass spectrum (HRMS). The results of bioassays indicated that most of the target compounds possessed excellent acaricidal activities against carmine spider mite larvae and eggs. Especially, diisopropylamino oxalyl compound 7g and piperidine oxalyl compound 7h were 1.4- and 2.3-fold as high as the activities of commercial Spiromesifen, respectively, against spider mite eggs. Moreover, most of the target compounds exhibited insecticidal activities against Lepidoptera pest. Interestingly, compounds containing alkylamino-substituted oxalyl moiety showed obvious selectivity between spider mite larvae and eggs because the activities against spider mite eggs of 7g and 7h were 25-fold those against spider mite larvae, whereas Spiromesifen had no significant differences in these activities. This meant that the introduction of an oxalyl moiety to spirocyclic tetronic acid might lead to novel biological activity characteristics.